Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

George Van Buren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7637-3717; OpenAlex author ID A5026127519. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 18

  1. Missed Opportunities for Multimodality Therapy in Resectable Pancreatic Cancer: National Disparities and Consequences for Survival. Co-author DOI 10.1002/jso.70408↗
  2. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Co-author DOI 10.1038/s41591-025-04043-5↗
  3. Tumor Immune Microenvironment Differences Associated With Racial Disparities in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2025.01.005↗
  4. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2553↗
  5. Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1274783↗
  6. Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2022.02.058↗
  7. Rapid diagnosis and tumor margin assessment during pancreatic cancer surgery with the MasSpec Pen technology. Co-author DOI 10.1073/pnas.2104411118↗
  8. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine Co-author DOI 10.1101/2021.11.29.470415↗
  9. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.11.012↗
  10. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Co-author DOI 10.1016/j.surg.2018.08.003↗
  11. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. Co-author DOI 10.1371/journal.pone.0213294↗
  12. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  13. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Co-author DOI 10.1016/j.surg.2017.05.003↗
  14. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Last author DOI 10.3390/nu9030243↗
  15. Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. Co-author DOI 10.18632/oncotarget.13704↗
  16. Pancreatic cancer disparities in African Americans. Last author DOI 10.1097/mpa.0000000000000323↗
  17. Pancreatic cancer: advances in treatment. First author DOI 10.3748/wjg.v20.i28.9354↗
  18. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pan… Co-author DOI 10.1245/s10434-013-3161-9↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ernest Ramsay Camp · 4 shared papers, 2022–2026 · strength 0.91
  2. Eric Jay Silberfein · 6 shared papers, 2015–2026 · strength 0.78
  3. Derek J. Erstad · 3 shared papers, 2023–2026 · strength 0.74
  4. William E. Fisher · 8 shared papers, 2014–2022 · strength 0.70
  5. Mark P. Rubinstein · 2 shared papers, 2023–2025 · strength 0.41
  6. Zachary Gao · 2 shared papers, 2023–2025 · strength 0.41
  7. John C. Johnson · 1 shared paper, 2026 · strength 0.33
  8. William E Fisher · 1 shared paper, 2026 · strength 0.33
  9. Benjamin Musher · 2 shared papers, 2015–2026 · strength 0.28
  10. Nader Nabile Massarweh · 3 shared papers, 2017–2019 · strength 0.22
  11. Hop S. Tran Cao · 3 shared papers, 2017–2019 · strength 0.22
  12. Ann Marie Leen · 1 shared paper, 2026 · strength 0.22
  13. Helen E Heslop · 1 shared paper, 2026 · strength 0.22
  14. Cliona M. Rooney · 1 shared paper, 2026 · strength 0.22
  15. Brandon George Smaglo · 1 shared paper, 2026 · strength 0.22
  16. Dafna Bar‐Sagi · 2 shared papers, 2021–2023 · strength 0.22
  17. Powel H. Brown · 2 shared papers, 2021–2023 · strength 0.22
  18. Kanchan Singh · 2 shared papers, 2021–2023 · strength 0.22
  19. Erika Yanil Faraoni · 2 shared papers, 2021–2023 · strength 0.22
  20. Vidhi Chandra · 2 shared papers, 2021–2023 · strength 0.22
  21. Curtis Jackson Wray · 2 shared papers, 2021–2023 · strength 0.22
  22. Altaf Mohammed · 2 shared papers, 2021–2023 · strength 0.22
  23. Nirav C Thosani · 2 shared papers, 2021–2023 · strength 0.22
  24. Florencia M. McAllister · 2 shared papers, 2021–2023 · strength 0.22
  25. Jennifer M. Bailey · 2 shared papers, 2021–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.